Latest Period
Q2 2026
CUSIP: 254604101
Latest Period
Q2 2026
Institutions Reporting
215
Shares (Excl. Options)
42,768,328
Price
$73.14
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
Latest holder context comes from 215 institutions filings for Q2 2026.
Security key
254604101
Latest holder period
Q2 2026
13F holders
215
13D/G owners
9
CIK / CUSIP context first
Broader feeds
Open recent reporting periods for CUSIP 254604101:
13D/G owners
Large-stake holder rows connected to Schedule 13D/G evidence.
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 13% | -9.3% | $365,416,699 | -$2,374,866 | 4,875,473 | -0.65% | FMR LLC | 30 Jun 2026 |
| AI DMI LLC | 8% | -25% | $199,459,837 | -$49,166,626 | 3,018,460 | -20% | AI DMI LLC | 20 Oct 2025 |
| RA CAPITAL MANAGEMENT, L.P. | 5.9% | $177,001,530 | 2,228,924 | RA Capital Management, L.P. | 30 Dec 2025 | |||
| ORBIMED ADVISORS LLC | 4.5% | $73,382,798 | 1,556,369 | ORBIMED ADVISORS LLC | 10 Mar 2025 | |||
| WELLINGTON MANAGEMENT GROUP LLP | 4.1% | -39% | $79,996,547 | -$50,911,307 | 1,432,090 | -39% | Wellington Management Group LLP | 30 Jun 2025 |
| Paradigm Biocapital Advisors LP | 3.5% | $57,097,283 | 1,210,971 | Paradigm BioCapital Advisors LP | 31 Mar 2025 | |||
| Frazier Life Sciences Public Fund, L.P. | 3% | $57,339,676 | 1,026,489 | Frazier Life Sciences Public Fund, L.P. | 30 Jun 2025 | |||
| Bain Capital Life Sciences Opportunities III, LP | 3.3% | $46,372,025 | 983,500 | Bain Capital Life Sciences Opportunities III, LP | 31 Dec 2024 | |||
| Atlas Venture Fund X, L.P. | 2.2% | -30% | $73,469,638 | -$24,517,376 | 813,167 | -25% | Atlas Venture Fund X, L.P. | 12 Dec 2025 |
As of 30 Jun 2026, 215 institutional investors reported holding 42,768,328 shares of Disc Medicine, Inc. - COMMON STOCK (IRON). This represents 112% of the company’s total 38,089,633 outstanding shares.
13F concentration
Largest 13F positions for this security by reported shares and value.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 13% | 4,894,473 | -12% | 0.02% | $357,981,753 |
| BlackRock, Inc. | 6.5% | 2,467,899 | +8.5% | 0% | $180,502,133 |
| RA CAPITAL MANAGEMENT, L.P. | 6.4% | 2,450,221 | 0% | 1.6% | $179,209,164 |
| JPMORGAN CHASE & CO | 4.9% | 1,875,795 | +37% | 0.01% | $139,868,053 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 4.9% | 1,875,399 | +21% | 0.01% | $137,168,000 |
| WELLINGTON MANAGEMENT GROUP LLP | 4.6% | 1,741,351 | +0.34% | 0.02% | $127,362,413 |
| STATE STREET CORP | 4.3% | 1,648,836 | -2.9% | 0% | $120,595,865 |
| Vestal Point Capital, LP | 4.1% | 1,550,000 | +121% | 2.6% | $113,367,000 |
| Atlas Venture Life Science Advisors, LLC | 4% | 1,513,875 | 0% | 13% | $110,724,818 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.6% | 1,369,027 | -0.47% | 0% | $100,130,635 |
| Frazier Life Sciences Management, L.P. | 3.6% | 1,354,852 | 0% | 2.2% | $99,093,875 |
| TCG Crossover Management, LLC | 3.5% | 1,341,862 | 0% | 2.4% | $98,143,787 |
| BVF INC/IL | 3% | 1,153,612 | -9.3% | 2.2% | $84,375,182 |
| Woodline Partners LP | 2.5% | 958,281 | 0% | 0.22% | $70,088,672 |
| Siren, L.L.C. | 2.3% | 888,401 | -10% | 1.3% | $64,977,649 |
| Logos Global Management LP | 2.3% | 875,000 | +56% | 2.8% | $63,997,500 |
| Opaleye Management Inc. | 2.2% | 855,000 | +103% | 5.7% | $62,534,700 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.1% | 789,724 | +6.1% | 0% | $57,772,342 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 1.7% | 657,000 | 0% | 0.5% | $48,052,980 |
| DIMENSIONAL FUND ADVISORS LP | 1.5% | 569,018 | +44% | 0.01% | $41,622,451 |
| Bellevue Group AG | 1.5% | 560,000 | +22% | 0.86% | $40,958,400 |
| Saturn V Capital Management LP | 1.4% | 524,730 | +17% | 5.5% | $38,378,752 |
| ARMISTICE CAPITAL, LLC | 1.2% | 460,000 | -14% | 0.93% | $33,644,400 |
| JENNISON ASSOCIATES LLC | 1.2% | 439,520 | -28% | 0.02% | $32,146,492 |
| Aberdeen Group plc | 1.2% | 438,174 | +17% | 0.04% | $32,048,046 |
Quarter history
Holder count, reported shares/value, and median price by quarter.
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 42,768,328 | $3,130,477,672 | +$68,860,332 | $73.14 | 215 |
| 2026 Q1 | 41,790,891 | $2,667,822,421 | +$184,842,529 | $63.94 | 201 |
| 2025 Q4 | 38,292,772 | $3,040,405,170 | +$327,723,771 | $79.41 | 196 |
| 2025 Q3 | 34,174,573 | $2,258,188,476 | +$16,098,753 | $66.08 | 164 |
| 2025 Q2 | 34,069,403 | $1,804,405,782 | +$52,373,227 | $52.96 | 148 |
| 2025 Q1 | 33,154,047 | $1,649,828,469 | +$313,979,403 | $49.64 | 155 |
| 2024 Q4 | 26,576,603 | $1,684,756,023 | -$53,215,124 | $63.40 | 151 |
| 2024 Q3 | 27,309,249 | $1,342,089,295 | -$26,632,908 | $49.14 | 130 |
| 2024 Q2 | 27,576,793 | $1,242,993,864 | +$212,594,407 | $45.07 | 119 |
| 2024 Q1 | 22,155,328 | $1,379,374,874 | +$124,372,681 | $62.26 | 125 |
| 2023 Q4 | 20,197,167 | $1,166,592,879 | +$18,737,189 | $57.76 | 111 |
| 2023 Q3 | 19,879,838 | $933,957,855 | +$42,877,645 | $46.98 | 90 |
| 2023 Q2 | 19,115,397 | $848,710,699 | +$223,083,623 | $44.40 | 89 |
| 2023 Q1 | 14,612,435 | $309,637,635 | +$77,103,451 | $21.19 | 45 |
| 2022 Q4 | 10,800,037 | $214,639,221 | +$202,496,221 | $19.89 | 30 |